GlassScriptPhysician profile
Jane Soyoung Clark
NPI 1659530004
$7,295.46
in general payments reported to CMS, 2019-2025
29 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $679 · 2021: $784 · 2022: $1,004 · 2023: $1,848 · 2024: $1,056 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.84 |
| Education | $316.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,586.37 | 2019-2025 | |
| Genzyme Corporation | $817.88 | 2019-2025 | |
| Janssen Biotech, INC. | $743.90 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $607.50 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $526.98 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $469.69 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $394.30 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $383.83 | 2019-2025 | Ilumya |
| Pfizer INC. | $320.97 | 2020-2025 | |
| Galderma Laboratories, L.P. | $197.38 | 2020-2025 | Nemluvio |
| Dermavant Sciences, INC. | $167.93 | 2022-2023 | Vtama |
| Ucb, INC. | $164.92 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $123.28 | 2022-2024 | Otezla |
| Genentech USA, INC. | $86.48 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $85.78 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $78.71 | 2021-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.84 | 2023-2024 | Cyltezo, Spevigo |
| Boston Scientific Corporation | $71.50 | 2023-2025 | Lumenis Pulse 120h, Wavewriter Alpha Prime 16 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.33 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $68.36 | 2020 | |
| Arcutis Biotherapeutics, INC. | $54.86 | 2023 | |
| Mayne Pharma Commercial LLC | $53.93 | 2021-2024 | |
| Menarini Silicon Biosystems, INC. | $41.36 | 2025 | |
| Incyte Corporation | $22.58 | 2024 | Opzelura |
| Botanix Sb INC | $21.44 | 2025 | Sofdra |
| Celgene Corporation | $19.61 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.13 | 2023 | Ycanth |
| Aclaris Therapeutics, INC. | $13.67 | 2019 | |
| Almirall LLC | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.